Researchers identify FGFR4, FLT1, and WNT5A as key biomarkers and suggest dovitinib and nintedanib as new targeted therapies ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

Biomarkers are pivotal for confirming diagnoses, predicting disease progression, and tailoring therapeutic modalities. Recent ...

In cancer patients, the health of the thymus—a key part of the body's immune system—is associated with the outcomes these ...

Three presentations at ESMO 2025 will demonstrate Lunit SCOPE IO’s value in predicting immunotherapy response in colorectal, ...

Results of a study led by researchers at Roswell Park Comprehensive Cancer Center are shedding light on why some newly ...

The health of the thymus - a key part of the body's immune system - is associated with cancer patients' outcomes to immune checkpoint inhibitor treatment, according to a ground-breaking international ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

Ohio State University scientists are applying artificial intelligence to predict which lobular breast cancer patients will ...

Merck (MRK) stock is in focus as its blockbuster drug Keytruda as part of a combo regimen hits a secondary goal in a Phase 3 ...

Ohio State University scientists are applying artificial intelligence to predict which lobular breast cancer patients will ...